Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

FORMA Therapeutics and Cancer Research Technology to Discover Cancer Drugs

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
Companies join in bold research initiative to discover innovative tools, technologies and therapeutic drug candidates against deubiquitinating enzymes (DUBs).

Under this agreement, FORMA will pair its ultra-efficient drug discovery capabilities with CRT’s expertise in translating academic discoveries through its Discovery Laboratories (CRT-DL) and the exclusive world-class academic network of CRUK Principal Investigators.

“This initiative with CRT and CRUK has the potential to significantly accelerate our understanding of the relevant biological applications of DUBs, a key class of enzymes involved in regulating protein homeostasis,” said Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics. “We are particularly looking forward to working closely in this initiative with CRT’s Discovery Laboratories and a group of preeminent investigators, who bring critical insights in this area of important biology and have proven track records in basic and translational research.”

Keith Blundy, CEO of Cancer Research Technology stated, “Cancer Research UK’s breadth of research combined with CRT-DL’s drug discovery capabilities are a unique platform that has secured the FORMA relationship and will contribute to bringing breakthrough cancer therapeutics to patients.”

Protein ubiquitination is involved in many cellular processes and its regulation is controlled in part by DUBs. Ubiquitin “tags” proteins for degradation, and DUBs remove this tag, providing a tool for manipulating protein levels (protein homeostasis) in a cell. Ubiquitin biology is therefore complex and important to a broad range of human diseases. FORMA and CRT-DL will leverage their combined strengths to explore the protease enzymes that regulate ubiquitin-dependent pathways implicated in cancer.

“DUBs represent an attractive area for drug discovery exploration. As key regulators of ubiquitin recycling, processing, proofreading and disassembly, there is a tremendous opportunity to build a franchise of complementary therapeutics targeting the diverse collections of protein complexes,” stated Kenneth W. Bair, Ph.D., Chief Scientific Officer and Head of Research and Development for FORMA Therapeutics. Dr. Bair further noted that a tremendous investment is being made by several groups to propel protein homeostasis research and discoveries into the practice of medicine.

As part of this agreement, a collaborative consortium will be formed consisting of FORMA Therapeutics Inc. and up to ten FORMA ADDCos (Asset Discovery and Development Company) subsidiaries, Cancer Research Technology – Discovery Laboratories (CRT-DL) and initially five Principal Investigators including:

•    Professors Michael Clague and Sylvie Urbé - University of Liverpool, Liverpool, UK
•    Dr. Benedikt Kessler – The University of Oxford, UK
•    Dr. David Komander – Medical Research Council, Laboratory of Molecular Biology, Cambridge, UK
•    Dr. Huib Ovaa – Chemical Biology Laboratory, Netherlands Cancer Institute, The Netherlands.

These investigators will focus on furthering the consortium’s understanding of biological and structural insights of DUBs, and assist the discovery teams to ensure the most relevant screening technologies and secondary characterization assays are deployed for selection of lead candidates. FORMA will provide research funding support and defined compensation payments for DUB-specific ADDCo programs that achieve specified milestones.

Rob Sarisky, Chief Business Officer, FORMA Therapeutics, stated, “We are pleased to have CRT participate as a cornerstone partner in FORMA’s launch of the ADDCo framework. This vehicle allows our not-for-profit collaborators to access a capital efficient engine operating at scale, attain financial returns mirroring their contributions and collectively advance medical science within the framework of a unified team.”

Harpal Kumar, Chief Executive of Cancer Research UK, added, “Our research is saving lives. We are making great progress in uncovering the causes of cancer to find better ways to tackle the disease. But there is much still to do and highly collaborative partnerships focused on novel biological pathways to deliver new treatments are urgently needed. This alliance with FORMA allows us to explore a very exciting emerging area of biology to identify and develop potential new cancer drugs that will hopefully benefit patients in the future.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FORMA Therapeutics and Celgene Corporation Establish Broad Strategic Collaboration
FORMA and Celgene will discover, develop and commercialize drug candidates to regulate protein homeostasis targets.
Wednesday, May 01, 2013
FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim to Develop Novel Oncology Drugs
The companies entered into a research and development partnership to discover and develop novel drug candidates for the treatment of cancer. The agreement will focus on discovering small molecule drugs against oncology-relevant protein-protein interactions.
Thursday, January 05, 2012
FORMA Therapeutics Grants Genentech Exclusive Rights to Acquire a Pre-clinical Cancer Program
FORMA Therapeutics enters into an agreement granting Genentech, exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.
Thursday, July 14, 2011
FORMA Therapeutics Announces Oncology Collaboration with Novartis
FORMA will utilize its cell-based screening platform to discover inhibitors for undisclosed protein-protein interaction for oncology.
Thursday, July 30, 2009
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
Human Stem Cells to Rapidly Generate Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Mechanism of Tuberculosis Infection
Researchers at UTSW Medical Center have identified a new way that tuberculosis bacteria get into the body, revealing a potential therapeutic angle to explore.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Eliminating Doubt in Criminal Investigations
New ASU certificate to help curb error, misunderstanding in the quest for justice.
Determination of 13 Organic Toxicants in Human Blood
Researchers have utilised liquid-liquid extraction coupling HPLC-MS/MS to identify and quantify organic toxicants in human blood.
A Novel Cell Culture Model For Forensic Biology Experiments
Researchers have developed a new cell culture model which provides an efficient research tool in forensic biology.
Rhino DNA Bank Aids Anti-Poaching Fight
At the University of Pretoria's Veterinary Genetics Laboratory (VGL) at Onderstepoort, Dr Cindy Harper and her team have developed a ground-breaking technique to collect and catalogue DNA from rhinos and rhino horns.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!